CRISPR Resources
Learn more about Myllia’s proof-of-concept single-cell CRISPR screens incl. biotechnology resources, posters, slide decks, and videos
General resources
Our Factsheet
Check out Myllia's technology platform enabling drug target discovery and functional genomics at single-cell resolution
Our Portfolio
At Myllia, pooled CRISPR screens are performed at large scale, and our unique platform involves a broad portfolio of CRISPR/Cas9 technologies
CRISPR-ready cancer cell lines for CRISPRn & CRISPRi screens
Browse through our catalogue of CRISPR-ready cancer cell lines for your next tailor-made CRISPR screens
Download Myllia’s company presentation: CRISPR screens for drug target discovery
At Myllia, we use the CROP-Seq technology to perturb cells with CRISPR and profile transcriptional outcomes by RNA sequencing at single-cell resolution.
Next-generation CRISPR screening for drug target discovery
De-risk target discovery and drug development using the best possible validated targets
CRISPR screens for immuno-oncology (IO) research
CROP-Seq (Perturb-Seq) in primary T cells - Utilize our tailor-made CRISPR screens to characterize your immuno-oncology drug candidates and CAR-T cell products
RESEARCH ARTICLE in Cell Reports, May 2024
Together with Boehringer Ingelheim, Myllia performed a CROP-Seq screen contributing to the publication: "Genetic dependencies associated with transcription factor activities in human cancer cell lines" in Cell Reports, May 2024
Posters
Poster | A genome-scale PARPi screen for synthetic lethality
At Myllia, we’ve performed a genome-scale CRISPR KO screen in HeLa cells to identify novel or well-known genes that are involved in DNA damage repair and would resemble gene pairs with PARP.
Poster | A genome-wide CROP-Seq screen reveals mediators of T cell signaling
The first-of-its-kind genome-scale CRISPRi screen was conducted to verify factors involved in TCR signaling pathways. Unravelling these T cell-intrinsic molecular factors could potentially unlock new therapeutic targets and strategies for modulating T cell responses in various immune-related disorders.
Poster | Large-scale single-cell CRISPR screens in primary human T cells
The CROP-seq experiment in pan T-cells involved a targeted single-cell RNA sequencing of 300 mRNAs. At Myllia, we can identify rare subsets, transitional states, and distinct functional profiles that may be masked in bulk analyses, providing a more comprehensive understanding of T cell activation and differentiation.
Poster | Single-cell CRISPR screens in primary human T cells identify regulators of Th2 cell skewing
T helper 2 (Th2) cell differentiation plays a critical role in regulating allergic responses, defense against parasites, and immune homeostasis. In a CROP-Seq experiment with CD4+ T cells, Th2-skewed cells were studied using a sgRNA library targeting 102 genes with a targeted read-out of 300 mRNAs.
Poster | Design of sgRNA libraries for CRISPRn screens
The design of sgRNAs for CRISPRn, CRISPRi and CRISPRa is a crucial factor determining the success of CRISPR screening experiments. Myllia´s proprietary sgRNA design algorithm selects highly active sgRNA sequences for targeting both essential and non-essential genes and appears to be “superior” to other publicly available libraries.
Slide decks
A genome-scale PARPi CRISPR KO screen for synthetic lethality
CRISPR KO screen at genome-scale in HeLa cells to identify novel or well-known genes that are involved in DNA damage repair to explore PARPi synthetic lethality gene pairs.
A genome-wide CROP-Seq CRISPRi screen for factors of TCR signaling
At Myllia, the Perturb-seq (CROP-seq) workflow has been adapted to enable genome-scale CRISPRi (CRISPR interference) screens in Jurkat cells at single-cell resolution. The first-of-its-kind genome-scale CRISPRi screen was conducted to verify factors involved in TCR signaling pathways.
Large-scale CROP-Seq screening in primary human T cells
At Myllia, we can identify rare subsets, transitional states, and distinct functional profiles that may be masked in bulk analyses, providing a more comprehensive understanding of T cell activation and differentiation. The CROP-seq experiment in pan T-cells involved a targeted single-cell RNA sequencing of 300 mRNAs.
A CROP-Seq screen for modulators of primary Th2 cell polarization
In a CROP-Seq experiment with CD4+ T cells, Th2-skewed cells were studied using a sgRNA library targeting 102 genes with a targeted read-out of 300 mRNAs.
Design of highly efficient sgRNA libraries for CRISPRn screens
The design of sgRNAs for CRISPRn, CRISPRi and CRISPRa is a crucial factor determining the success of CRISPR screening experiments. Myllia´s proprietary sgRNA design algorithm selects highly active sgRNA sequences for targeting both essential and non-essential genes and appears to be “superior” to other publicly available libraries.
Videos
Video | About us
Discover the unique CRISPR screening portfolio developed at Myllia Biotechnology
Video | How do CRISPR screens work?
Explore how we can use CRISPR screens to support drug target identification
Video | CRISPR/Cas9-based screens: CRISPRko vs. CRISPRi
Learn more about the differences of CRISPR/Cas9-based CRISPRko (knockout) and CRISPRi (interference) screens
Video | CROP-Seq: Single-cell CRISPR screening
Learn how the CROP-Seq (Perturb-Seq) technology at Myllia can help to elucidate novel drug targets at single-cell resolution
Video | Targeted sequencing
Would you like to know more about targeted sequencing applications? Explore how tailored PCR panels can boost the NGS read-outs of your next CRISPR screens
Video | Primary human T cell CRISPR screening
At Myllia, CRISPR screens are performed in primary human T cells to explore factors of T cell activation, differentiation and exhaustion. Learn more about our CROP-seq technology to boost CAR-T and TCR-T cell potency!